Evidence map›Paper›PMID 42447316›Full record

ArticleJournal of proteome research2026

Instrument-Software Synergy in Proteomics: Systematic Evaluation across Mass Spectrometry Platforms, Search Engines, and Rescoring Methods.

Sander Heyndrickx, Robbin Bouwmeester, Arthur Declercq, Robbe Devreese, Magnus Palmblad, Wout Bittremieux, Tess Av Afanasyeva, Joel Lapin, Arzu Tugce Guler, Pierre-Olivier Schmit and 3 more

Abstract read
In one paragraph

Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sander HeyndrickxCompOmics, VIB-UGent Center for Medical Biotechnology, VIB , Ghent9000, Belgium.ORCID 0009-0004-1818-8619
Robbin BouwmeesterCompOmics, VIB-UGent Center for Medical Biotechnology, VIB , Ghent9000, Belgium.ORCID 0000-0001-6807-7029
Arthur DeclercqCompOmics, VIB-UGent Center for Medical Biotechnology, VIB , Ghent9000, Belgium.ORCID 0000-0002-9376-1399
Robbe DevreeseCompOmics, VIB-UGent Center for Medical Biotechnology, VIB , Ghent9000, Belgium.ORCID 0000-0002-3432-1502
Magnus PalmbladCenter for Proteomics and Metabolomics, Leiden University Medical Center, Postbus 9600 2300 RCLeiden, The Netherlands.ORCID 0000-0002-5865-8994
Wout BittremieuxDepartment of Computer Science, University of Antwerp, Antwerpen2020, Belgium.ORCID 0000-0002-3105-1359
Tess Av AfanasyevaSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam1066 CX, Netherlands.
Joel LapinComputational Mass Spectrometry, TUM School of Life Sciences, Technical University of Munich, Freising85354, Germany.
Arzu Tugce GulerInstitute for Experiential AI, Northeastern University, Boston, Massachusetts02115, United States.
Pierre-Olivier SchmitBruker France SAS, Wissembourg67160, France.
Christine CarapitoBioOrganic Mass Spectrometry Laboratory (LSMBO), IPHC UMR 7178, University of Strasbourg, CNRS, Strasbourg67000, France.ORCID 0000-0002-0079-319X
Lennart MartensCompOmics, VIB-UGent Center for Medical Biotechnology, VIB , Ghent9000, Belgium.ORCID 0000-0003-4277-658X
Ralf GabrielsCompOmics, VIB-UGent Center for Medical Biotechnology, VIB , Ghent9000, Belgium.ORCID 0000-0002-1679-1711

Funding

Agence Nationale de la Recherche ANR-10-INBS08-03Agence Nationale de la Recherche ANR-24-INBS-0015Agence Nationale de la Recherche UAR2048CHIST-ERA G0GDV23NFonds Wetenschappelijk Onderzoek 12A6L24NFonds Wetenschappelijk Onderzoek 12AK526NFonds Wetenschappelijk Onderzoek 1SH9O24NHORIZON EUROPE Health 101080544
6 · The paper itself

Abstract

Mass spectrometry-based proteomics has advanced through parallel improvements in instrumentation (mass spectrometers) and software (data analysis), yet whether these improvements interact synergistically or provide diminishing returns remains unclear. Here, we systematically evaluate instrument-software coevolution across eight mass spectrometry platforms, three generations of search engines, and multiple rescoring approaches, yielding 72 unique instrument-software combinations spanning from 2004 to 2024. Our results reveal that instrumentation and software improvements produce synergistic rather than substitutive benefits. Here, machine learning-based rescoring consistently recovers identifications from low-intensity precursors that produce noisier, more challenging spectra. Crucially, because of increased sensitivity and speed, modern instruments detect more low-intensity precursors, thereby increasing the population of challenging spectra for which rescoring provides the greatest benefit. However, this expanded detection depth comes at a cost: recovered low-abundance peptides exhibit inherently higher quantification error, creating a fundamental trade-off between proteome coverage and quantification accuracy. Together, these findings provide a systematic overview of how instrument and software advances have jointly shaped proteomics performance over the past two decades.

Indexed as

Mass SpectrometryProteomeProteomicsSearch EngineSoftwareMachine LearningPeptidesPeptidesProteomedata analysisevaluationinstrumentsmachine learningmass spectrometrypeptide identificationpeptide quantificationproteomics

Identifiers

PMID42447316
PMCPMC13459558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.